Jacobs Levy Equity Management
NTGN

Jacobs Levy Equity Management’s Neon Therapeutics, Inc. Common Stock NTGN Stock Holding History

Jacobs Levy Equity Management’s Portfolio NTGN Stock Details NTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-188,277
Closed -$222K – 1152
2019
Q4 		$222K Buy
188,277
+32,658
+21% +$52.2K ﹤0.01% 921
2019
Q3 		$268K Buy
155,619
+45,058
+41% +$137K ﹤0.01% 800
2019
Q2 		$524K Sell
110,561
-24,032
-18% -$135K 0.01% 735
2019
Q1 		$869K Buy
134,593
+79,639
+145% +$417K 0.01% 691
2018
Q4 		$276K Buy
+54,954
New +$385K ﹤0.01% 823

Other funds holding NTGN

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Athanor Capital New York $24.6M AUM 2.49% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $1.82B AUM 26.23% 1-Year Est. Return
MS
Maven Securities St Helier, Jersey $5.2B AUM 44.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jacobs Levy Equity Management's NTGN Position: Q1 2020 in Review

Jacobs Levy Equity Management sold out of Neon Therapeutics, Inc. Common Stock (NTGN) in Q1 2020, closing a stake of 188,277 shares — an estimated $222K sold.

Jacobs Levy Equity Management first reported a position in NTGN in Q4 2018 and held it in 5 quarters. The position peaked at $869K in Q1 2019. 43 funds tracked by Wall St. Rank hold NTGN as of Q1 2020.

  • Jacobs Levy Equity Management reported no remaining Neon Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 188,277 Neon Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $222K.
  • Jacobs Levy Equity Management first reported a position in Neon Therapeutics, Inc. Common Stock in Q4 2018 and held it in 5 quarters.
  • Jacobs Levy Equity Management's Neon Therapeutics, Inc. Common Stock position peaked at $869K in Q1 2019.
  • 43 funds tracked by Wall St. Rank held Neon Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2020, filed 15 May 2020.